JP2008295460A - Serotype identification method for enterovirus - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a rapid and easy serotype identification method for enterovirus. <P>SOLUTION: The serotype of enterovirus is identified by carrying out molecular systematic analysis, based on the base sequence of whole region of VP4 of enterovirus. The serotype of enterovirus in a sample is rapidly and easily identified by preparing RNA from the sample, obtaining a cDNA from the prepared RNA, amplifying the base sequence including base sequence of the VP4 region by PCR from the cDNA, and obtaining the base sequence of the whole region of the VP4, by carrying out a base sequence analysis using the amplified product. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention relates to an enterovirus serotype identification method.

  Enteroviruses mainly infect enteric cells, as the name derives from the Greek word “enteron” for “intestine”, pediatric paralysis, aseptic meningitis, herpangina, upper respiratory tract inflammation, limbs It is a causative virus that causes various clinical symptoms such as illness, diarrhea, rash, myocarditis, pneumonia and bronchitis. Enteroviruses are resistant to acids and can easily pass through the stomach to reach the lower intestinal tract, where it grows. It may also be the etiology of hepatitis (CAV4, CAV9) or cause a global pandemic of acute hemorrhagic conjunctivitis like EV70 and CAV24 mutants. No other virus genus can cause so many different clinical symptoms. Therefore, this virus is one of the most frequently isolated viruses at virus inspection agencies, and approximately 4000 to 6000 isolation reports in Japan each year.

  Enteroviruses are small spherical viruses that have a plus single-stranded RNA in their genome that is contained in the family Picornaviridae genus Enterovirus. In humans, it is classified into 68 serotypes including poliovirus 1-3, coxsackievirus A1-A22 and A24, coxsackievirus B1-B6, echovirus 1-9, 11-27 and 29-34, enterovirus 68-71. Yes. Coxsackievirus A23 was later found to be Echovirus 9, Echovirus 10 was reovirus type 1, and Echovirus 28 was human rhinovirus 1A, which are now missing. It is difficult to estimate the serotype of these viruses from clinical symptoms, and the identification of the isolated virus is performed by a neutralization test using type-specific immune sera.

  Enteroviruses, like many other RNA viruses, are replicated by RNA-dependent RNA polymerase encoded by the viral gene itself. However, since this enzyme does not have a proofreading function, base mutations generated during RNA synthesis are accumulated in the gene of the progeny virus. Therefore, when a base mutation accompanied by an amino acid mutation occurs in the virus structural protein region, a so-called hardly neutralizing virus may be generated. This is an inherent problem that is always associated with neutralization tests using phenotype as an index.

On the other hand, classification of enteroviruses from the viewpoint of molecular biology has been attempted (Non-Patent Documents 1 to 4), but it cannot be said to be sufficient for identifying serotypes. For example, phylogenetic classification of enterovirus genotypes is said not to reflect serotypes.
P. Muir et al., 1998, Clin. Microbiol. Rev., 11: 202-227 RR Rueckert, 1996, Fields Virolgy, 3rd.ed., Lippincott-Raven Publishers, 609-654 T. Poyry et al., 1996, J. Gen. Virol., 77: 1699-1717 T. Pulli et al., 1995, Virology, 212: 30-38

  An object of the present invention is to provide a rapid and simple serotype identification method for enteroviruses that does not have the above-mentioned problems.

  The present inventors analyzed the base sequence of the entire VP4 region of Enterovirus, which has been reported to be isolated in the Japanese epidemic, and obtained the knowledge that a serotype can be identified by molecular phylogenetic analysis of this base sequence. Based on this, the present invention has been completed.

  Thus, the present invention is an enterovirus serotype identification method (hereinafter, also referred to as the present invention identification method) characterized in that molecular phylogenetic analysis is performed based on the base sequence of the enterovirus VP4 region and the enterovirus serotype is identified. I will provide a.

  In the identification method of the present invention, the base sequence of the VP4 region is prepared by preparing RNA from a sample, obtaining cDNA from the prepared RNA, amplifying the base sequence including the base sequence of the VP4 region by PCR from the obtained cDNA, It can obtain by performing a base sequence analysis using the manufactured product.

  Examples of the primer used for PCR include a primer having the base sequence shown in SEQ ID NO: 1 and a primer having the base sequence shown in SEQ ID NO: 2.

  According to the present invention, it is possible to determine the serotype of enterovirus by molecular phylogenetic analysis of the base sequence without requiring separate culture of enterovirus.

  The identification method of the present invention is characterized in that molecular phylogenetic analysis is performed based on the base sequence of the VP4 region of enterovirus in order to identify the serotype of enterovirus.

  In the present specification, the VP4 region means a region (207 bp) encoding a VP4 protein (69 amino acids) that is one of the proteins forming the capsid of enterovirus. Further, the base sequence of the VP4 region means a part thereof having a sufficient length (usually 20 bp or more) to reflect the base sequence or serotype of the entire region of the VP4 region.

  The method for obtaining the base sequence of the VP4 region is not particularly limited, but when obtaining the base sequence of the VP4 region from a sample containing an unidentified enterovirus of the serotype, the following method is preferred. That is, RNA is prepared from a sample, cDNA is obtained from the prepared RNA, a base sequence including the base sequence of the VP4 region is amplified from the obtained cDNA by PCR, and base sequence analysis is performed using the amplified product. Is the method.

  The sample is not particularly limited as long as it contains or may contain enterovirus, but examples include clinical materials such as pharyngeal wiping fluid, cerebrospinal fluid, blister contents, or separated from these clinical materials. And virus culture medium. RNA can be prepared from these samples by a known method. A method for preparing cDNA from RNA is also known. PCR can be performed according to a known PCR method using the cDNA as a template and an oligonucleotide selected so as to amplify a base sequence including the base sequence of the VP4 region. In addition, cDNA can be obtained and DNA can be amplified in the same reaction system by reverse transcription (RT) -PCR from RNA.

  The amplification product can be obtained by a known method such as separation by agarose gel electrophoresis, extraction from the gel, and extraction purification. Usually, an amplification product having a length predictable from the known base sequence of enterovirus and the base sequence of the primer used is obtained.

Examples of the oligonucleotide selected so that the base sequence including the entire region of the VP4 region can be amplified include the oligonucleotide consisting of the base sequence shown in SEQ ID NO: 1 and the oligonucleotide consisting of the base sequence shown in SEQ ID NO: 2. .

  Amplification by PCR may be performed in two stages. For example, the first PCR was performed using an oligonucleotide consisting of the base sequence shown in SEQ ID NO: 1 and an oligonucleotide consisting of the base sequence shown in SEQ ID NO: 2 as primers. Thereafter, the second PCR may be performed using the oligonucleotide consisting of the base sequence shown in SEQ ID NO: 1 and the oligonucleotide consisting of the base sequence shown in SEQ ID NO: 3 as primers. By performing amplification in two stages, it becomes possible to amplify the target base sequence more specifically.

The base sequence of the amplification product can be determined by a known method. Of the determined base sequences, the base sequence of the VP4 region is used for system analysis.
In the identification method of the present invention, the phylogenetic analysis based on the base sequence of the VP4 region can be performed by a known phylogenetic analysis method. Examples of such methods include the Higgins method, the UPGMA method using the two-parameter method, the NJ method, and the like, and software for performing phylogenetic analysis by these methods is commercially available (DNASIS ( Hitachi Software Engineering), SINCA (Fujitsu), etc.).

  The serotype can be determined by whether or not the serotype shows a homology of a certain value or more with a standard strain of each serotype in the phylogenetic analysis, or is distinguished from other serotype clusters with a probability of a certain value or more. The constant value may be a value that allows each strain belonging to each serotype to form a single cluster in the phylogenetic tree obtained by phylogenetic analysis.

  More specifically, the homology is 80% or more, and the probability of being distinguished from other clusters by the bootstrap method is 90% or more. For example, according to the phylogenetic analysis of enterovirus standard strain 44 serotype (60 strains), serotypes are distinguished by 84% homology, and bootstraps with isolates are distinguished from other serotypes with a probability of 100%. It was.

  EXAMPLES Next, the present invention will be described in detail with reference to examples. However, the following examples are given only as an aid for obtaining specific recognition about the present invention, and thereby the scope of the present invention is limited in any way. It is not a thing.

[Example 1] Nucleotide sequence analysis of the entire enterovirus VP4 region In order to analyze the nucleotide sequence of the entire enterovirus VP4 region, which has been reported to be isolated in the Japanese epidemic, the following standard strains, namely Coxsackie A group, were used as viruses As viruses (CAV), CAV2, CAV3, CAV4, CAV5, CAV6, CAV7, CAV8 and CAV10, 8 strains, Coxsackie group B virus (CBV), 2 strains CBV2 and CBV6, and Echovirus (ECV), ECV1, ECV2, ECV3, ECV4, ECV5, ECV7, ECV13, ECV14, ECV17, ECV18, ECV19, ECV20, ECV24, ECV25 and ECV30, a total of 26 serotype strains were used.

  As clinical specimens, pharyngeal wiping fluid, cerebrospinal fluid, blister contents, and virus culture fluids separated from these clinical materials were used. The pharyngeal wipe and the water bubble contents were suspended in 1.5 ml of TE solution (10 mM Tris-HCl, 1 mM EDTA (pH 8.0)) and stored at −80 ° C. for use.

RNA was extracted from 100 μl of each sample using Sumitest R kit (Sumitomo Metal Industries), and 8 μl of RNase-free distilled water and 1 μl of ribonuclease inhibitor (40 U / μl) were added to the dried RNA. Promega) and 1 μl of 50 μM downstream primer (OL68-1, 5′GGTAA (C / T) TTCCACCACCA (A / G / C / T) CC3 ′, 20mer (SEQ ID NO: 1)) were added and dissolved. After heating at 100 ° C. for 1 minute, it was quenched in ice. To this, 2 μl of 10 × Taq buffer (100 M Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl ₂ , 0.01% (w / v) gelatin), 2 μl of 10 mM dNTPs
Then, 1 μl of M-MLV-derived reverse transcriptase (200 U / μl) (BRL) and 4 μl of RNase-free distilled water were added, and cDNA was synthesized under the reaction conditions of 37 ° C. for 60 minutes.

In order to amplify the nucleotide sequence of the entire VP4 region of the virus, PCR was performed using primers set in the 5 ′ untranslated region and the VP2 region that have sequences common to enteroviruses. In the first round (1st) PCR, 10 μTaq buffer 4.5 μl, 40 μM upstream primer (EVP2, 5′CCTCCGGCCCCTGAATGCGGCTAAT3 ′, 25mer (SEQ ID NO: 2)) 0.5 μl, 39.75 μl of distilled water and Ampli Taq DNA polymerase (5 U / μl) (Roche Diagnostic
Systems) 0.25 μl, mineral oil overlay, 40 cycles of denaturation at 95 ° C. for 30 seconds, annealing at 55 ° C. for 30 seconds and extension at 72 ° C. for 1 minute using GeneAmp PCR System 9600 (PERKIN ELMER) Cycle conditions were performed. The second (2nd) PCR was performed by adding 10 μTaq buffer 4.5 μl, 10 mM dNTPs 1 μl, 50 μM upstream primer (EVP4, 5′CTACTTTGGGTGTCCGTGTT3 ′, 20mer (SEQ ID NO: 3)) to 5 μl of the reaction solution obtained in the 1st PCR. 5 μl, 50 μM downstream primer (OL68-1) 0.5 μl, distilled water 38.25 μl and Ampli Taq DNA polymerase (5 U / μl) 0.25 μl were added, and the same conditions as in 1st PCR were performed. PCR products were separated by 3% agarose gel electrophoresis, detected with ultraviolet light after ethidium bromide staining.

  In PCR under this condition, about 750 bp is amplified by 1st PCR, and about 650 bp is amplified by 2nd PCR (including a part of the 5 ′ untranslated region, the entire VP4 region, and about 1/3 of the N-terminal side of the VP2 region). Amplification was confirmed in all the standard strains and isolated virus strains used this time.

  In addition to the amplification described above, amplification of about 620 bp was observed from the clinical sample of the throat swab by 2nd PCR. This is considered to be a rhinovirus belonging to the same Picornaviridae family as the enterovirus, and has the primer sequence used this time, but has a partial base sequence deletion in the 5 'untranslated region. Can be easily distinguished from enteroviruses.

  The base sequence of the PCR product obtained in this manner and including the entire VP4 region was analyzed. The PCR product was dissolved in distilled water so that the unreacted primers and dNTPs were removed using a QIAquick PCR purification kit (QIAGEN), and the DNA concentration was 5 ng / μl or more. For base sequence analysis, a primer (SEVP1, 5′TGGCTGCTTATGGTGACAAT3 ′, 20mer (SEQ ID NO: 4)) was designed based on the base sequence common to the enterovirus upstream of the VP4 region. Base sequence analysis was performed using a dideoxy terminator cycle sequence kit (PERKIN ELMER) for 25 cycles at 95 ° C for 10 seconds, 50 ° C for 5 seconds and 60 ° C for 4 minutes, and 373A DNA autosequencer (PERKIN ELMER ) To determine the nucleotide sequence.

  As a result of determining the nucleotide sequence, no insertion or deletion was observed in the nucleotide sequence of any of the enterovirus standard strain, isolated virus strain, and clinical specimen, and the VP4 region was uniform with a length of 207 bp. .

  CAV2-8, CAV10, CBV2, CBV6, ECV1-5, ECV7, ECV13, ECV14, ECV17-21, ECV24, ECV25, and ECV30 (26 serotypes) are the first virus standard strains for which the nucleotide sequence of the entire VP4 region was analyzed. CAV9, CAV16, CAV21, CAV24, CBV1, CBV3-5, ECV6, ECV9, ECV11, ECV12, ECV16, EV70, EV71, PV1-3 (18 serotype 35 strains) standard strains registered in GenBank It is. The VP4 regions of these 44 serotype enterovirus standard strains had 66-84% homology, and serotypes could be distinguished by 80% homology.

According to RT-PCR under the above conditions, it is possible to directly amplify the viral genome from clinical materials such as pharyngeal wipes and cerebrospinal fluid with a detection sensitivity of 0.1TCID ₅₀ . Therefore, rapid identification of enterovirus serotypes becomes possible without separate culture.

[Example 2] Serotype identification of clinical isolates by phylogenetic analysis 26 standard strains newly analyzed for nucleotide sequences in Example 1 and CAV9, CAV16, CAV21, CAV24, CBV1, CBV3 registered in GenBank , CBV4, CBV5, ECV6, ECV9, ECV11, ECV12, ECV16, EV70, EV71 and PV1-3 (18 serotype 35 strains) VP4 region base sequences were selected. The phylogenetic tree was created by the Higgins method (DNASIS, Hitachi Software Engineering), and the UPGMA method and NJ method (SINCA, Fujitsu) using the two-parameter method. Statistical evaluation was performed using the bootstrap method (SINCA).

Serotype identification was performed by branching of the phylogenetic tree and bootstrap analysis obtained by phylogenetic analysis of the base sequence of clinical isolates together with the standard strain.
First, as a result of creating a phylogenetic tree based on the nucleotide sequence of the entire VP4 region of the standard strain, the enterovirus genotype was divided into 5 groups with about 60% homology. That is, CAV2-8, CAV10 group 1, CAV16, EV71 group 2, CBV1-6, CAV9, Echovirus (ECV) group 3, Poliovirus (PV), CAV21, CAV24 group 4 and Each group of the fifth group of EV70. This is similar to the UPGMA method and the NJ method, and does not contradict the phylogenetic tree in the genome within the Picornaviridae family. Furthermore, the group of VP4-VP2 amino acid sequences shown by Peter Muir et al. It was very similar to dividing.

  Next, a phylogenetic analysis of 36 clinical isolates of hand-foot-and-mouth disease was conducted, and CAV16 and EV71 identified with serotypes showed 80% or more homology with the standard strains of each serotype. A single serotype cluster of CAV16 and EV71, respectively, was formed with 100% probability in the strap method without crossing. Furthermore, a single cluster was also formed for strains with unidentified serotypes.

  Similarly, when a phylogenetic analysis was performed on 14 ECV30 isolates, it showed a homology of 80% or more with the ECV30 standard strain, and formed a single cluster with 100% probability by the bootstrap method. It was.

  Furthermore, for each isolate of Coxsackievirus A24 mutant strain (CAV24v), when a phylogenetic analysis was performed in the same manner, a single cluster (85% or more homology) was formed with the standard strain, and then 100% by the bootstrap method. A single cluster was formed with no probability of crossing and was easily differentiated from other serotype enteroviruses. Two viruses, CAV24v and EV70, are known as the causative viruses of acute hemorrhagic conjunctivitis (AHC). Therefore, it was confirmed that the causative virus of AHC can be rapidly identified without separate culture.

Claims (6)

  The base sequence of the entire VP4 region of enterovirus in the sample is amplified, and the base sequence of the entire VP4 region is obtained by determining the base sequence of the amplified product. The obtained base sequence is the same region of the serotype standard strain A method of identifying an enterovirus serotype, characterized by performing a molecular phylogenetic analysis based on the nucleotide sequence of and identifying an enterovirus serotype in a sample.   The method according to claim 1, wherein the enterovirus in the sample is a standard strain or isolate of enterovirus.   Oligonucleotide selected so that base sequence amplification can prepare RNA from the sample, obtain cDNA from the prepared RNA, and amplify the base sequence including the base sequence of the entire VP4 region using the obtained cDNA as a template The serotype identification method according to claim 1 or 2, wherein the method is carried out using as a primer.   The serotype identification method according to claim 3, wherein the primer comprises a primer comprising the base sequence shown in SEQ ID NO: 1 and the base sequence shown in SEQ ID NO: 2.    The serotype identification method according to any one of claims 1 to 3, wherein the standard strains are all standard strains belonging to the enterovirus group.   In the molecular phylogenetic analysis, the serotype identification method shows a homology of 80% or more with the standard strain of each serotype, or a single cluster with a value higher than the single cluster formation value by the bootstrap method. The serotype identification method according to any one of claims 1 to 5, wherein the serotype identification method is performed using formation as an index.